The Collaborative R&D Terms and Agreements in Pharma, Biotech and
Diagnostics report provides comprehensive understanding and
unprecedented access to the collaborative R&D deals and agreements
entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why
companies enter collaborative R&D deals.

Understanding the flexibility of a prospective partner's negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered and rights transferred - contract documents provide this
insight where press releases and databases do not.

This report contains links to online copies of actual collaborative R&D
contract documents as submitted to the Securities Exchange Commission by
biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a
prospective partner's flexibility on a wide range of important issues,
many of which will have a significant impact on each party's ability to
derive value from the deal.